Please login to the form below

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

EMA clears BMS’ oral multiple sclerosis drug Zeposia

On the injectable/infusion side, Roche’s anti-CD20 antibody Ocrevus (ocrelizumab) is already a big seller with sales of $3.8bn last year, and has just been approved by the

Latest news

J&J aims for US approval of MS drug ponesimod

A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).
Biogen triumphs over Mylan’s Tecfidera patent challenge

language. Although the patent dispute is an overwhelming win, Biogen has been facing other challenges in the MS market from new treatments, including Novartis’ newly-approved Mayzent and Roche’s Ocrevus.
Roche posts minor sales miss in Q4 as biosimilar pressure grows

Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely Perjeta (pertuzumab) for HER2-positive breast cancer, Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy Hemlibra (emicizumab) and
Novartis gets EU approval for multiple sclerosis therapy Mayzent

In recent years, drugs such as Roche’s Ocrevus have improved the treatment options available to patients with relapsing-remitting multiple sclerosis and the primary progressive form of the disease.
Mylan, Biocon’s Herceptin biosimilar launched in US

Roche is also counting on its new-generation products to help counter the offset of cut-price biosimilar competition, such as multiple sclerosis therapy Ocrevus (ocrelizumab), PD-L1 Tecentriq (atezolizumab) and

More from news
Approximately 19 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....